Observational analysis shows enhanced efficacy of 177Lu-PSMA-617 in metastatic prostate cancer, indicating a need for innovative treatment strategies.
More effective treatments for metastatic prostate cancer (mPC) are needed as disease progression remains universal. 177Lu-PSMA-617 radiopharmaceutical therapy (RPT)—Pluvicto (Novartis)—was first approved for the treatment of castration-resistant prostate cancer (PC) based on the landmark VISION
No takes yet. Share an insight, caveat, or question.
Karmann et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: